<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="https://www.taxtmi.com/rss_sitemap/rss_feed_blog.xsl?v=1750492856"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>1991 (9) TMI 309 - CEGAT, NEW DELHI</title>
    <link>https://www.taxtmi.com/caselaws?id=112687</link>
    <description>For tariff classification of Prolita Syrup, the decisive test was whether the product was understood and marketed in trade as a medicinal preparation or as a food supplement. The evidence showed it was marketed as a food supplement, the drug authorities had not treated it as a drug, and municipal licensing supported food-item treatment; trade notice and HSN notes also indicated that vitamin syrups may fall within food supplements. Mere therapeutic value, dosage directions, brand presentation, colour scheme, or prescription-oriented sale was insufficient to convert it into a patent or proprietary medicine. The product therefore remained classifiable as a food supplement, and the Revenue failed to displace the lower authority&#039;s view.</description>
    <language>en-us</language>
    <pubDate>Fri, 27 Sep 1991 00:00:00 +0530</pubDate>
    <lastBuildDate>Tue, 01 May 2012 13:00:57 +0530</lastBuildDate>
    <generator>TaxTMI RSS Generator</generator>
    <atom:link href="https://www.taxtmi.com/rss_feed_blog?id=149703" rel="self" type="application/rss+xml"/>
    <item>
      <title>1991 (9) TMI 309 - CEGAT, NEW DELHI</title>
      <link>https://www.taxtmi.com/caselaws?id=112687</link>
      <description>For tariff classification of Prolita Syrup, the decisive test was whether the product was understood and marketed in trade as a medicinal preparation or as a food supplement. The evidence showed it was marketed as a food supplement, the drug authorities had not treated it as a drug, and municipal licensing supported food-item treatment; trade notice and HSN notes also indicated that vitamin syrups may fall within food supplements. Mere therapeutic value, dosage directions, brand presentation, colour scheme, or prescription-oriented sale was insufficient to convert it into a patent or proprietary medicine. The product therefore remained classifiable as a food supplement, and the Revenue failed to displace the lower authority&#039;s view.</description>
      <category>Case-Laws</category>
      <law>Central Excise</law>
      <pubDate>Fri, 27 Sep 1991 00:00:00 +0530</pubDate>
      <guid isPermaLink="true">https://www.taxtmi.com/caselaws?id=112687</guid>
    </item>
  </channel>
</rss>